Molecule
Perfluorohexyloctane is a semifluorinated alkane indicated for the treatment of the signs and symptoms of dry eye disease (DED). It is available as ophthalmic solution. MedsAcross supplies Perfluorohexyloctane for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
MIEBO ® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for treatment of the signs and symptoms of dry eye disease.
Source: US FDA prescribing information
Perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. The exact mechanism of action for MIEBO in DED is not known.
Source: US FDA prescribing information
Instill one drop of MIEBO four times daily into each eye. Recommended Dosage Instill one drop of MIEBO four times daily into affected eye(s). Contact lenses should be removed prior to and for at least 30 minutes after the administration of MIEBO.
Source: US FDA prescribing information
Hypersensitivity. Hypersensitivity MIEBO is contraindicated in patients with a history of hypersensitivity reaction to perfluorohexyloctane.
Source: US FDA prescribing information
Use with Contact Lenses MIEBO should not be administered while wearing contact lenses. Advise patients that contact lenses should be removed prior to and for at least 30 minutes after administration of MIEBO.
Source: US FDA prescribing information
Most common ocular adverse reaction was blurred vision. Blurred vision was reported in less than 4% of individuals.
Source: US FDA prescribing information
Storage Store MIEBO at 15ºC to 25ºC (59ºF to 77ºF).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Perfluorohexyloctane, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Miebo 1 mg/mg ophthalmic solutionOphthalmic | Bausch & Lomb | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 18 May 2023 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Perfluorohexyloctane in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Perfluorohexyloctane and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Perfluorohexyloctane, including Miebo.
Yes. The US FDA first approved Perfluorohexyloctane on 18 May 2023, according to Drugs@FDA.
No listed presentation of Perfluorohexyloctane is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.